Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Co-treatment with pegvisomant and somatostatin analogue in acromegaly
2007-005244-25Phase 4Completed
- Sponsor
- Department of Endocrinology and Internal Medicine
- Start
- Oct 2007
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4 trial of pegvisomant, lanreotide and octreotide in acromegaly (2 arms), sponsored by Department of Endocrinology and Internal Medicine. Primary endpoints: Insulin sensitivity, Glucose tolerance and 1 more. Started Oct 2007; status: completed.
02
Drugs
pegvisomantlanreotideoctreotide
03
Conditions
acromegaly
Beyond the preview
Go deeper on 2007-005244-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-005244-25.